Long acting antiretroviral compounds are changing HIV prevention by providing alternatives to daily oral medication. These medicines work by maintaining protective drug concentrations in the body over extended periods. Injectable prevention options can help individuals who experience difficulties with daily medication schedules. Understanding their mechanisms, administration schedules, effectiveness, and limitations helps explain their role in modern HIV prevention strategies.
Long acting antiretroviral compounds are medications designed to prevent HIV infection by maintaining effective drug concentrations in the body for extended periods. They are primarily used as pre-exposure prophylaxis (PrEP), a prevention approach for individuals who do not have HIV but may have an increased risk of exposure.
Unlike conventional oral PrEP, which generally requires daily medication, long acting compounds are administered through injections at scheduled intervals. Two important medications used for long acting injectable HIV prevention are cabotegravir and lenacapavir.
Cabotegravir belongs to the integrase strand transfer inhibitor (INSTI) class. It prevents HIV from integrating its genetic material into human immune cells. Lenacapavir is a capsid inhibitor that interferes with the HIV capsid, a protein structure essential for several stages of the viral life cycle.
These compounds provide different approaches to maintaining protection against HIV. Their longer dosing intervals may help individuals who experience difficulties following daily medication schedules.
Several antiretroviral compounds are being studied or used in long acting HIV prevention strategies. Their mechanisms, administration methods, and dosing intervals differ.
1. Cabotegravir
Cabotegravir is a long acting injectable medication used for HIV pre-exposure prophylaxis. It works by blocking the integrase enzyme, which HIV requires to insert its genetic material into human cells.
Important characteristics include:
Administered through intramuscular injections.
Generally given initially and again after one month.
Maintenance injections are administered every two months.
Provides an alternative to daily oral PrEP.
Requires regular HIV testing and clinical monitoring.
2. Lenacapavir
Lenacapavir is a long acting capsid inhibitor used for HIV prevention. It interferes with the protective protein shell of HIV, disrupting essential stages of viral replication.
Its important characteristics include:
Administered through subcutaneous injections every six months.
Requires an initial dosing schedule that includes oral medication.
Offers an alternative for individuals who prefer less frequent administration.
Requires HIV testing before starting and during continued use.
Has demonstrated high effectiveness in clinical trials.
The World Health Organization recommended lenacapavir as an additional PrEP option in July 2025.
Long acting antiretroviral compounds have expanded the available approaches to HIV prevention. Clinical research has demonstrated that these medications can significantly reduce the risk of acquiring HIV when administered according to recommended schedules.
The effectiveness of these compounds depends on appropriate patient selection, correct administration, and continued clinical monitoring. HIV testing is particularly important because starting or continuing preventive medication without identifying an existing infection may contribute to drug resistance.
Common considerations include:
Injection site reactions: Pain, swelling, redness, or tenderness may occur following administration.
HIV testing: Testing is necessary before initiating treatment and at recommended follow-up intervals.
Dosing schedules: Missing scheduled injections may reduce protective drug concentrations.
Drug resistance: Undiagnosed HIV infection during PrEP use can increase the possibility of resistance.
Follow-up care: Healthcare professionals assess medication tolerance, exposure risks, and continued prevention requirements.
Long acting PrEP does not prevent other sexually transmitted infections. Additional prevention approaches, including condom use and regular sexual health screening, remain important.
The choice between oral and injectable PrEP depends on individual circumstances, medical history, preferences, and clinical recommendations. These medications are intended for people who are HIV-negative and should not be confused with injectable antiretroviral treatment combinations used to manage established HIV infection